<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00466310</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00008577</org_study_id>
    <secondary_id>8370</secondary_id>
    <nct_id>NCT00466310</nct_id>
  </id_info>
  <brief_title>Metabolic Signatures and Biomarkers in Schizophrenia</brief_title>
  <official_title>Metabolic Signatures and Biomarkers in First Episode and Recurrent Patients With Schizophrenia in Comparison to Healthy Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We plan to use a metabolomics lipid platform to map biochemical signatures in unmedicated
      schizophrenic patients prior to and 4 weeks post treatment with the antipsychotic drug
      aripiprazole and compare that to lipid perturbations induced by risperidone. These drugs have
      inherently different risk for metabolic adverse effects and patients respond to them
      differently. Metabolic signatures for the drugs capture significant biochemical information
      that could explain part of the basis for varied drug response within individuals and will
      highlight pathways implicated in drug action and in disease pathogenesis possibly enabling
      new drug design strategies. In addition, we will compare patients to healthy controls at
      baseline in regard lipid profiles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schizophrenia (SCH) is a devastating mental disease that affects the human population
      worldwide with an incidence of about 1%. Most individuals with this illness benefit from
      long-term pharmacotherapy, however, the therapeutic effects of antipsychotic treatment are
      inconsistent, incomplete, and often countered by significant side-effects associated with
      long-term physical morbidity (e.g., tardive dyskinesia, obesity, hyperglycemia,
      hyperlipidemia. Metabolomics is a powerful new technology that provides a snap shot of
      biochemical pathways at a particular point in time. It has been earmarked as an important
      area to develop under the NIH roadmap initiative. We plan to use this platform to map
      biochemical signatures in unmedicated schizophrenic patients prior to and 4 weeks post
      treatment with the antipsychotic drug aripiprazole and compare that to lipid perturbations
      induced by risperidone. These drugs have inherently different risk for metabolic adverse
      effects and patients respond to them differently. Metabolic signatures for the drugs capture
      significant biochemical information that could explain part of the basis for varied drug
      response within individuals and will highlight pathways implicated in drug action and in
      disease pathogenesis possibly enabling new drug design strategies.In addition, we will
      compare patients to healthy controls at baseline in regard lipid profiles, to assess whether
      lipid profiles differ between unmedicated schizophrenia patients and healthy controls.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Plasmalogen Levels in the Lipid Profile</measure>
    <time_frame>Baseline</time_frame>
    <description>Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological disorders show decreased level of plasmalogens.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Aripiprazole for 4 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood is drawn for baseline. 20 Subjects are randomly assigned to receive Aripiprazole for weeks weeks with a starting dose of 10mg/day and the dose will be titrated to a maximum of 30mg /day based on effectiveness and tolerability. After 4 weeks of treatment, blood will be drawn again for metabolomics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone for 4 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood will be drawn for baseline evaluation. 20 Subjects will be randomly assigned to receive risperidone at a starting dose of 2mg/day, and can be increased to 6mg/day based on response of the subject. After 4 weeks of medication, blood is drawn again.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fasting blood samples will be drawn from healthy volunteers to match age, race and gender with the research subjects for comparison.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Aripiprazole for 4 weeks</description>
    <arm_group_label>Aripiprazole for 4 weeks</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Subjects will be randomized to risperidone for 4 weeks</description>
    <arm_group_label>Risperidone for 4 weeks</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Healthy volunteers</intervention_name>
    <description>Healthy volunteers</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-60 years

          -  Diagnosis of schizophrenia

          -  Actively psychotic

          -  No more than a single dose of antipsychotic in the preceding 2 weeks

        Exclusion Criteria:

          -  Mental retardation, epilepsy or history of head trauma

          -  Substance use disorder that explains the majority of the psychopathology

          -  Pregnant or lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rima Kaddurah-Daouk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John Umstead Hospital</name>
      <address>
        <city>Butner</city>
        <state>North Carolina</state>
        <zip>27509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5. Epub 2003 Jul 25.</citation>
    <PMID>12883005</PMID>
  </reference>
  <results_reference>
    <citation>Kaddurah-Daouk R, McEvoy J, Baillie R, Zhu H, K Yao J, Nimgaonkar VL, Buckley PF, Keshavan MS, Georgiades A, Nasrallah HA. Impaired plasmalogens in patients with schizophrenia. Psychiatry Res. 2012 Aug 15;198(3):347-52. doi: 10.1016/j.psychres.2012.02.019. Epub 2012 Apr 16.</citation>
    <PMID>22513041</PMID>
  </results_reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2007</study_first_submitted>
  <study_first_submitted_qc>April 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2007</study_first_posted>
  <results_first_submitted>April 5, 2011</results_first_submitted>
  <results_first_submitted_qc>November 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 3, 2013</results_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Metabolomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Unmedicated patients treated for a first psychotic episode (n = 20), and patients treated for psychotic relapse of schizophrenia or schizoaffective disorder(n = 20).
Controls who had no personal history of psychotic illness or relatives with psychotic illnesses,(n = 31). Individuals receiving treatment for diabetes or hyperlipidemia were excluded.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>First Episode Schizophrenics</title>
          <description>Schizophrenia subjects with no prior episodes</description>
        </group>
        <group group_id="P2">
          <title>Recurrent Episode Schizophrenics</title>
          <description>Schizophrenia subjects with at least one prior episode</description>
        </group>
        <group group_id="P3">
          <title>Healthy Volunteers</title>
          <description>Fasting blood samples were drawn at baseline from 31 healthy matched controls.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>First Episode Schizophrenics</title>
          <description>These are subjects with no prior schizophrenic episodes</description>
        </group>
        <group group_id="B2">
          <title>Recurrent Episode Schizophrenics</title>
          <description>These subjects have had at least one prior schizophrenic episode.</description>
        </group>
        <group group_id="B3">
          <title>Healthy Volunteers</title>
          <description>Fasting blood samples were drawn at baseline from 31 healthy matched controls.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="71"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" spread="9.8"/>
                    <measurement group_id="B2" value="36.6" spread="12.7"/>
                    <measurement group_id="B3" value="37.9" spread="9.1"/>
                    <measurement group_id="B4" value="33.63" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Plasmalogen Levels in the Lipid Profile</title>
        <description>Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological disorders show decreased level of plasmalogens.</description>
        <time_frame>Baseline</time_frame>
        <population>17 of the 31 available controls were age and BMI matched to the schizophrenia subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>First Episode Schizophrenics</title>
            <description>Schizophrenia subjects with no prior episodes</description>
          </group>
          <group group_id="O2">
            <title>Recurrent Episode Schizophrenics</title>
            <description>Schizophrenia subjects with at least one prior episode</description>
          </group>
          <group group_id="O3">
            <title>Healthy Volunteers</title>
            <description>Fasting blood samples were drawn at baseline from 31 healthy matched controls.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Plasmalogen Levels in the Lipid Profile</title>
          <description>Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological disorders show decreased level of plasmalogens.</description>
          <population>17 of the 31 available controls were age and BMI matched to the schizophrenia subjects.</population>
          <units>nmoles/gram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.65" spread="14.37"/>
                    <measurement group_id="O2" value="59.57" spread="15.87"/>
                    <measurement group_id="O3" value="75" spread="19.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A wilcoxon rank sum test was performed comparing baseline plasmalogen values, comparing schizophrenia subjects vs controls.P values from this analysis were adjusted for false discovery rates by the method of Storey and Tribshiani.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0149</p_value>
            <p_value_desc>Unadjusted p value is .0041</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>First Episode Schizophrenics</title>
          <description>These are subjects with no prior schizophrenic episodes</description>
        </group>
        <group group_id="E2">
          <title>Recurrent Episode Schizophrenics</title>
          <description>These subjects have had at least one prior schizophrenic episode.</description>
        </group>
        <group group_id="E3">
          <title>Healthy Volunteers</title>
          <description>Fasting blood samples were drawn at baseline from 31 healthy matched controls.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited to patients admitted to Psychiatric facility</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Rima Kaddurah-Douk, Associate Professor</name_or_title>
      <organization>DUMC</organization>
      <phone>919-684-2611</phone>
      <email>rima.kaddurah-daouk@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

